Not a good buy right now: price action is breaking down (closed at 0.1702, well below listed supports), and the dominant trend remains bearish.
The near-term setup is being driven by a reverse split to regain Nasdaq compliance, which typically adds uncertainty and selling pressure rather than attracting sustained dip-buying.
With no bullish proprietary signals and weak fundamentals (no revenue, widening losses), the risk/reward does not favor an impatient entry.
Momentum: MACD histogram above 0 (0.000883) but positively contracting, suggesting any rebound momentum is fading.
RSI (6): 28.316 (near oversold), which can enable brief bounces, but does not override the larger bearish trend.
Key levels: Pivot 0.225; supports listed at 0.212 / 0.204, but the stock closed at 0.1702, implying a breakdown below support and a technically damaged chart.
may help restore Nasdaq $1 minimum bid compliance and reduce immediate delisting pressure.
Neutral/Negative Catalysts
Reverse stock split (1-for-25) effective Feb 5, with trading adjustments Feb 6; these events often coincide with selling pressure and renewed volatility.
Post-market move (-19.40%) indicates traders are reacting negatively to the corporate action.
Technical breakdown: price is below cited support levels, increasing downside/trend-continuation risk.
Ongoing weak operating profile (no revenue base and losses) reduces support for sustained rallies.
Financial Performance
Latest quarter: 2025/Q3
Revenue: 0 (no meaningful operating revenue; YoY shown as 0.00%).
Net income: -1,793,651, down 18.17% YoY (loss widened).
EPS: -0.08, down 78.95% YoY (material deterioration).
Overall: fundamentals show continued cash burn/negative earnings without top-line traction.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data provided, so a Wall Street pros/cons trend assessment cannot be confirmed from the dataset.
Practical read-through from available data: the key market focus is listing compliance (reverse split) rather than improving fundamentals, which typically aligns with a cautious/negative professional stance.
Wall Street analysts forecast ADIL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.5 USD with a low forecast of 1.5 USD and a high forecast of 1.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ADIL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.5 USD with a low forecast of 1.5 USD and a high forecast of 1.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.425
Low
1.5
Averages
1.5
High
1.5
Current: 3.425
Low
1.5
Averages
1.5
High
1.5
Maxim
Hold
to
Buy
upgrade
$1.50
AI Analysis
2025-09-30
Reason
Maxim
Price Target
$1.50
AI Analysis
2025-09-30
upgrade
Hold
to
Buy
Reason
Maxim upgraded Adial Pharmaceuticals to Buy from Hold with a $1.50 price target.
